Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
Novocure Ltd - SIC # 2836 - BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC SUBSTANCES
Ticker
Exchange
SIC #
Website
Latest Ticker
NVCR
Nasdaq
2836
https://www.novocure.com/
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for Novocure Ltd
How Many Insiders Sold NovoCure Limited (NASDAQ:NVCR) Shares?
- Jan 23rd, 2019 9:38 am
Novocure Ltd (NVCR) CEO Asaf Danziger Sold $9 million of Shares
- Jan 18th, 2019 4:15 pm
Tamarack Capital Management’s Return, AUM, and Holdings
- Jan 11th, 2019 10:24 am
Novocure Announces Fourth Quarter and Full Year 2018 Operating Statistics, Preliminary Net Revenues and Provides Company Update
- Jan 7th, 2019 2:05 pm
Stocks down in December for pharma firms in the Triangle
- Dec 27th, 2018 7:23 am
Is NovoCure a Buy?
- Dec 24th, 2018 7:44 am
Novocure to Participate in the 37th Annual J.P. Morgan Healthcare Conference
- Dec 21st, 2018 5:30 am
What Kind Of Shareholder Owns Most NovoCure Limited (NASDAQ:NVCR) Stock?
- Dec 17th, 2018 12:20 pm
Novocure and the AACR Announce Four Inaugural Research Grants to Promote and Support Innovative Research on Tumor Treating Fields
- Dec 17th, 2018 5:30 am
Is NovoCure Limited (NVCR) A Good Stock To Buy?
- Dec 16th, 2018 7:10 am
3 Top Medical Device Stocks to Buy Now
- Dec 12th, 2018 9:49 am
Why Portola Pharmaceuticals’ Stock Price Is Plummeting Today
- Dec 11th, 2018 12:04 pm
Recent Analysis Shows Moody's, Hershey, NovoCure, Mohawk Industries, La-Z-Boy, and Lockheed Martin Market Influences — Renewed Outlook, Key Drivers of Growth
- Dec 7th, 2018 5:55 am
Sub-Group Analysis of Novocure’s EF-14 Phase 3 Pivotal Trial in Newly Diagnosed Glioblastoma Published in Journal of Neuro-Oncology Demonstrating More Time on Optune® Predicted Increased Survival
- Dec 6th, 2018 5:30 am
Novocure and Zai Lab Awarded Deal of the Year at 5th Annual BioCentury China Healthcare Summit in Shanghai, China
- Nov 14th, 2018 5:30 am
3 Top Healthcare Stocks to Buy in November
- Nov 13th, 2018 6:01 pm
Novocure Announces More than 70 Presentations on Tumor Treating Fields at 23rd Annual Meeting of the Society for Neuro-Oncology
- Nov 13th, 2018 6:24 am
Novocure and Zai Lab to Host Investor Event
- Nov 7th, 2018 2:00 pm
NovoCure Limited (NASDAQ:NVCR): Is Breakeven Near?
- Nov 7th, 2018 10:25 am
Scroll